
he standard care for inoperable stage III non-small cell lung cancer (NSCLC) involves chemoradiotherapy (CRT) followed by one year of checkpoint inhibitor (CPI) therapy. The optimal duration of CPI is unclear. This study examined the relationship between circulating tumor DNA (ctDNA) minimal residual disease (MRD) and outcomes in patients with short-course consolidation immunotherapy post-CRT. Analysis of ctDNA from plasma samples showed that detectable ctDNA linked to inferior progression-free survival (PFS). Patients with decreasing or undetectable ctDNA had better outcomes. Findings suggest that ctDNA MRD analysis can personalize the duration of CPI therapy.
Like
Save
Share